



(51) International Patent Classification:

C07D 471/10 (2006.01) **A61P 3/04** (2006.01)
C07D 519/00 (2006.01) **A61P 3/10** (2006.01)
A61K 31/4747 (2006.01)

(21) International Application Number:

PCT/IB2011/051035

(22) International Filing Date:

11 March 2011 (11.03.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/315,522 19 March 2010 (19.03.2010) US
 61/444,401 18 February 2011 (18.02.2011) US

(71) Applicant (for all designated States except US): **PFIZER INC.** [US/US]; 235 East 42nd Street, New York, New York 10017 (US).


(72) Inventors; and

(75) Inventors/Applicants (for US only): **BHAT-TACHARYA, Samit Kumar** [IN/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, Connecticut 06340 (US). **CAMERON, Kimberly O'-Keefe** [US/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, Connecticut 06340 (US). **FERNANDO, Dilinie Prasadhini** [US/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, Connecticut 06340 (US). **KUNG, Daniel Wei-Shung** [US/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, Connecticut 06340 (US). **LONDREGAN, Allyn Timothy** [US/US]; Pfizer

[Continued on next page]


(54) Title: 2,3 DIHYDRO-1H-INDEN-1-YL- 2,7-DIAZASPIRO [3.6] NONANE DERIVATIVES AND THEIR USE AS ANTAGONISTS OR INVERSE AGONISTS OF THE GHRELIN RECEPTOR

Human Dispersed Islet GSIS and CTLs
 1hr incubation with glucose $\pm$ cts
 4000 cells/well



Comparisons of Means				
Response = Insulin				
Model	Treatment	Dif	s.e.d	95% Conf Int
3 vs 11		91	43.9	3 179
11 vs 11+ CPD A		190	43.9	102 278
11 vs 11+ CPD B		122	43.9	34 210
11 vs 11+ CPD C		119	43.9	30 207
				p-value
				0.044
				0.000
				0.008
				0.009

(57) Abstract: The present invention provides a compound of Formula (I) or a pharmaceutically salt thereof wherein R¹, R², Ra, L, Z, Z¹ and Z² are as defined herein, that act as Ghrelin antagonists or inverse agonists; pharmaceutical compositions thereof; and methods of treating diseases, disorders, or conditions mediated by the antagonism of the Ghrelin receptor.



(I)



Global Research and Development, Eastern Point Road, Groton, Connecticut 06340 (US). **MCCLURE, Kim Francis** [US/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, Connecticut 06340 (US). **SIMILA, Suvi Tuula Marjukka** [FI/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, Connecticut 06340 (US).

(74) **Agent:** **BENSON, Gregg C.**; c/o Pfizer Inc. Eastern Point Road, MS 9114, Groton, Connecticut 06340 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to the identity of the inventor (Rule 4.17(i))*
- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*